GERN
Geron Corporation
$1.12
+$0.02(+1.82%)
52
Overall
60
Value
45
Tech
--
Quality
Market Cap
$695.81M
Volume
7.31M
52W Range
$1.04 - $4.21
Target Price
$3.43
Company Overview
| Mkt Cap | $695.81M | Price | $1.12 |
| Volume | 7.31M | Change | +1.82% |
| P/E Ratio | -4.0 | Open | $1.08 |
| Revenue | $77.0M | Prev Close | $1.10 |
| Net Income | $-174.6M | 52W Range | $1.04 - $4.21 |
| Div Yield | N/A | Target | $3.43 |
| Overall | 52 | Value | 60 |
| Quality | -- | Technical | 45 |
No chart data available
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), ImmunityBio (IBRX) and Geron (GERN)
Catie Powers•18 days ago
Barclays Sticks to Its Buy Rating for Geron (GERN)
TipRanks Auto-Generated Intelligence Newsdesk•19 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GERN | $1.12 | +1.8% | 7.31M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |